LUMINARY THERAPEUTICS, INC.
Allogeneic gamma-delta T cell therapy expressing BAFF-targeted chimeric antigen receptors (BAFF-CAR) for mantle cell lymphoma treatment
- Sector
- Biotech
- Headquarters
- Minneapolis, MN
- Founded
- 2019
- Latest Form D
- $1.4M, Nov 2025
- Total capital
- $14.8M
- Federal grants
- $3.4M
- 6 awards · 2020–2025
- Rank in peer group#245 of 514
- Private capital raised
- $11.4M
- 6 Form D · last Nov 2025
- 12 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 4 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$1.4M
- Federal grantHealth and Human S · Phase II · Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies$1.5M
- Private capital raisedForm D · SEC · 5th filing$5.2M
- Federal grantHealth and Human S · Phase I · An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma$399K
- Federal grantHealth and Human S · Phase I · Allogeneic BAFF Ligand Based CAR T-Cells as a Novel Therapy for Systemic Lupus Erythematous$300K
- Federal grantHealth and Human S · Phase I · Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies$398K
- Private capital raisedForm D · SEC · 4th filing$2.2M
- Private capital raisedForm D · SEC · 3rd filing$375K
- Private capital raisedForm D · SEC · 2nd filing$825K
- Private capital raisedForm D · SEC · 1st filing$1.5M
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase I · Simultaneous Targeting of Tumor and Stroma Cells to Enhance Solid Tumor CAR-T Cell Therapy$400K
- Federal grantHealth and Human S · Phase I · MyD88 fusion protein with antigen specific T Cell therapy for enhanced response in solid tumors$397K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#245 · top 48%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexander NaydichDirectorNamed in SEC Form D filings
- Branden MoriarityDirectorNamed in SEC Form D filings
- David LargaespadaExecutive Officer, Director, PromoterNamed in SEC Form D filings
- George CoxDirectorNamed in SEC Form D filings
- James HaymakerDirector, PromoterNamed in SEC Form D filings
- Jeff LiterExecutive Officer, Director, PromoterNamed in SEC Form D filings
Show all 13 people
- Jeff RossDirectorNamed in SEC Form D filings
- Jim HaymakerDirectorNamed in SEC Form D filings
- John HurleyExecutive OfficerNamed in SEC Form D filings
- John WellsDirectorNamed in SEC Form D filings
- Mark ChanceDirectorNamed in SEC Form D filings
- Peter KosaDirectorNamed in SEC Form D filings
- Tracey LodieDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 4- PendingDual-action Antigen-presenting Gamma Delta Car T-cellsUSPTOApplication PCTUS2025059890
- PendingMethods Of Generating Populations Of Therapeutic CellsUSPTOApplication PCTUS2025021010
- PendingDual-action Antigen-presenting Gamma Delta Car T-cellsUSPTOApplication 63735144
Show all 4 patent records
- Dual-action Antigen-presenting Gamma Delta Car T-cellsApplication PCTUS2025059890Pending
- Methods Of Generating Populations Of Therapeutic CellsApplication PCTUS2025021010Pending
- Dual-action Antigen-presenting Gamma Delta Car T-cellsApplication 63735144Pending
- Methods Of Generating Populations Of Therapeutic CellsApplication 63568877Pending
Related companies, and why
- DualitasSimilar federal contract value in Biotech · null in contracts
- PROGNOSYS BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- OnKure, Inc.Similar federal contract value in Biotech · null in contracts
- Numab TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ARTIFICIAL CELL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- RADOPTICS, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .